Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | POLB | P06746 | 3/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | GALR2 | O43603 | 1/20 | 0.60 |
| ▸ | MITF | O75030 | 1/20 | 0.60 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.60 |
| ▸ | XBP1 | P17861 | 1/20 | 0.60 |
| ▸ | CCR6 | P51684 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.44 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8178217 | 0.87 | AKR1C3 (0.53) | SMN1; SMN2ALDH1A1POLBHPGDLMNA | |
| SCHEMBL28550137 | 0.85 | ALDH1A1 (0.53) | SMN1; SMN2ALDH1A1POLBHPGDLMNA | |
| SCHEMBL3266352 | 0.84 | LMNA (0.55) | SMN1; SMN2ALDH1A1POLBHPGDLMNA | |
| SCHEMBL9721603 | 0.81 | ALDH1A1 (0.58) | SMN1; SMN2ALDH1A1POLBHPGDLMNA | |
| SCHEMBL3828291 | 0.80 | ALDH1A1 (0.53) | SMN1; SMN2ALDH1A1POLBHPGDLMNA | |
| SCHEMBL28493216 | 0.80 | AKR1C3 (0.55) | SMN1; SMN2ALDH1A1POLBHPGDLMNA | |
| SCHEMBL5967621 | 0.79 | LMNA (0.43) | SMN1; SMN2ALDH1A1POLBHPGDLMNA | |
| SCHEMBL28721663 | 0.79 | TSHR (0.48) | SMN1; SMN2ALDH1A1POLBLMNAGAA | |
| SCHEMBL28720949 | 0.79 | TSHR (0.68) | SMN1; SMN2ALDH1A1POLBLMNAKMT2A | |
| SCHEMBL11577236 | 0.79 | MAPT (0.44) | SMN1; SMN2POLBLMNANPSR1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1472213-B1 | PROCESS FOR THE SYNTHESIS OF N-ACYL-2-AMINO-4-ALKOXY-5-NITROBENZOIC ACIDS | WYETH LLC (US) | 2010-06-09 | — | — | EP | disclosed |
| US-7294740-B2 | Process for the synthesis of N-acyl-2-amino-4-alkoxy-5-nitrobenzoic acids | WYETH (US) | 2007-11-13 | — | — | US | disclosed |
| US-20070219394-A1 | Process for the synthesis of N-acyl-2-amino-4-alkoxy-5-nitrobenzoic acids | WYETH (US) | 2007-09-20 | — | — | US | disclosed |
| US-7227037-B2 | Process for the synthesis of N-nacyl-2-amino-4-alkoxy-5-nitrobenzoic acids | WYETH (US) | 2007-06-05 | — | — | US | disclosed |
| EP-1263503-B1 | USE OF CYANOQUINOLINES FOR TREATING OR INHIBITING COLONIC POLYPS | WYETH CORP (US) | 2005-11-02 | — | — | EP | disclosed |
| EP-1549297-A2 | STABILIZED PHARMACEUTICAL COMPOSITION CONTAINING BASIC EXCIPIENTS | Wyeth Holdings Corporation (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20050085662-A1 | Process for the synthesis of nacyl-2-amino-4-alkoxy-5-nitrobenzoic acids | WYETH (US) | 2005-04-21 | — | — | US | disclosed |
| EP-1472213-A1 | PROCESS FOR THE SYNTHESIS OF N-ACYL-2-AMINO-4-ALKOXY-5-NITROBENZOIC ACIDS | Wyeth (US) | 2004-11-03 | — | — | EP | disclosed |
| US-20040122048-A1 | Stabilized pharmaceutical composition containing basic excipients | WYETH HOLDINGS CORPORATION | 2004-06-24 | — | — | US | disclosed |
| WO-2004032909-A2 | STABILIZED PHARMACEUTICAL COMPOSITION CONTAINING BASIC EXCIPIENTS | WYETH HOLDINGS CORPORATION (US) | 2004-04-22 | — | — | WO | disclosed |
| WO-2003066575-A1 | PROCESS FOR THE SYNTHESIS OF N-ACYL-2-AMINO-4-ALKOXY-5-NITROBENZOIC ACIDS | WYETH (US) | 2003-08-14 | — | — | WO | disclosed |
| EP-1263503-A2 | USE OF CYANOQUINOLINES FOR TREATING OR INHIBITING COLONIC POLYPS | AMERICAN CYANAMID COMPANY (US) | 2002-12-11 | — | — | EP | disclosed |
| US-6384051-B1 | ANTITUMOR AGENTS | AMERICAN CYANAMID COMPANY | 2002-05-07 | — | — | US | disclosed |
| WO-2001068186-A2 | USE OF CYANOQUINOLINES FOR TREATING OR INHIBITING COLONIC POLYPS | AMERICAN CYANAMID COMPANY (US) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219394-A1 | Process for the synthesis of N-acyl-2-amino-4-alkoxy-5-nitrobenzoic acids | NAAA, ARSA, ACMSD | SMN1; SMN2 1470/4885ALDH1A1 1206/4885POLB 2167/4885 |
| US-20050085662-A1 | Process for the synthesis of nacyl-2-amino-4-alkoxy-5-nitrobenzoic acids | NAAA, ACMSD, ASNS | SMN1; SMN2 2190/4885ALDH1A1 1292/4885POLB 949/4885 |
| US-20040122048-A1 | Stabilized pharmaceutical composition containing basic excipients | F7, H1-10, F12 | SMN1; SMN2 3518/4885ALDH1A1 3199/4885POLB 3887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.